ERBB2 and breast neoplasm: In 13.8% of the patients, the breast tumor was 5 cm or larger before NACT, and 47% had estrogen receptor-negative (ER−) disease, whereas 64.7% had human epidermal growth factor receptor 2-positive (HER2+) disease.